OSE Immunotherapeutics is Pleased to Announce the Continuation of its Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011 in Ulcerative Colitis after the Interim Futility Analysis

NEXT STORY
Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021
PREV STORY
Apellis and Sobi Report Empaveli™ (pegcetacoplan) Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Maddie’s Fund Names Dr. Julie Levy As 2017 Avanzino Leadership Award Recipient

Pleasanton, CA, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Maddie's Fund®, a national family foundation ...

author_avatar
NASDAQ Market News

Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

DUBLIN, Ireland, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical ...

author_avatar
NASDAQ Market News

resTORbio Reports Second Quarter 2018 Financial Results

Phase 2b results identify dose and patient population for pivotal program with RTB101 Initiation ...

author_avatar
NASDAQ Market News